Dan leads the US Corporate & Government Affairs team and is responsible for communications, government affairs, policy and patient advocacy across AstraZeneca’s BioPharmaceutical Business Unit and Oncology Business Unit. He serves as a member of the US Leadership Team. 

Before assuming his current role in 2023, he was Country President of AstraZeneca Ireland since 2021. Dan joined AstraZeneca in 2004 and has held various leadership roles, including Executive Director, Value Strategy within the US Market Access Team, where he oversaw the development and delivery of innovative value strategies, gross-to-net contract, and channel strategies for US Oncology and BioPharmaceutical Business Units. Additionally, he held roles within Market Access, Marketing, and Sales Leadership at AstraZeneca, MedImmune, and GSK. 

Rick R. Suárez is the President of AstraZeneca Spain and Site Leader of the AstraZeneca Global Hub in Barcelona. Since joining the company in 2020, he has led a period of remarkable transformation, driving substantial sales growth and expanding the workforce from 800 to over 2,000 employees. Under his leadership, Spain has become one of AstraZeneca’s top three global leaders in clinical trials, particularly in Oncology, while the company’s corporate reputation in Spain has surged from 10th to 3rd in MRS rankings, a testament to his vision and commitment to innovation. 

Suárez’s leadership has been crucial in driving growth across multiple therapeutic areas, including Cardiovascular, Renal and Metabolism (CVRM), Respiratory, Immunology, Vaccines, and Immunotherapies. His focus on fostering public-private collaboration, enhancing market access, and aligning government relations with AstraZeneca’s broader goals has been instrumental in expanding patient access to life-changing medicines, including the Oncology portfolio. These efforts have not only advanced AstraZeneca’s market position but also resulted in strong, sustainable sales growth across the company. 

In addition to his business leadership, Suárez is a passionate advocate for talent development, diversity, and inclusion. He serves as President of the AstraZeneca Foundation in Spain, an organization dedicated to supporting young scientific talent and leads Fundamentales, an association focused on mental health in the workplace. A proud member of the LGBTI+ community, Suárez actively works to promote well-being and inclusivity across industries. 

With over 25 years of experience at AstraZeneca, Suárez has held senior roles in sales, marketing, medical affairs, market access, and government relations. Prior to his role in Spain, he served as Senior Vice President of Market Access in the U.S., where he led initiatives to improve patient access to therapies and support healthcare system sustainability.  

Pam Ganju is a VP in Eisai’s EMEA headquarters in the U.K and is the commercial lead for their Oncology and Neurology portfolio in the UK and Ireland. She also manages the Oncology alliance for the EMEA region. In her UK role, Pam represents Eisai on the ABPI Small Companies Committee (SCC). Over the last 17 years at Eisai, Pam has held multiple roles including the Global lead for Halaven (eribulin) a novel chemotherapy agent indicated for metastastic breast cancer that has been launched world-wide. Before Eisai, Pam worked in Novartis, and Bristol Myer-Squibb, in roles spanning several aspects of drug development. Pam received her doctorate from Imperial College, University of London (UK) in Molecular Biochemistry. Her postdoctoral fellowship studies were conducted in developmental biology at the Ludwig Institute for Cancer Research (UK) and in chronic pain at the Novartis Institute for Medical Sciences.

Mark has led our healthcare Advisory business for the last 3 years and is a commercial leader and business strategist, with a passion for healthcare transformation, technology, and market development. He has over 18 years of experience across the Healthcare industry, including Johnson and Johnson, with roles including Sales, Marketing and Commercial leadership, Consulting, Advisory, Transformation and Strategic capabilities. Mark has a broad experience working with clients across the Healthcare market, including pharma, medical devices and consumer health, spanning several specialties and therapy areas, bringing together a broad experience of working across the public healthcare sector in both primary, secondary and specialist care. His work has supported sales & marketing, large scale organisational change, service and strategy redesign, including the development and delivery of opportunity assessment, value stream and pathway mapping, go-to-market strategy, knowledge curation, launch excellence, technology landscaping, and patient and user-centric design initiatives including needs and value-based assessment and demand spaces integrating insights into actionable strategy.